Semaglutide vs tirzepatide: how to actually choose

It's the most-asked question in the GLP-1 conversation. Searches for "semaglutide vs tirzepatide" outnumber searches for "tirzepatide" alone in some months. The answer most articles give is a version of "tirzepatide loses more weight, choose tirzepatide if you can." That's directionally true and practically incomplete. The real answer depends on five things, and only one of them is the headline weight-loss number.

The headline number first, since it's what everyone leads with. In direct head-to-head trials and in matched cohort comparisons, tirzepatide produces about 5-7 percentage points more weight loss on average than semaglutide at the highest tolerated dose. Roughly 22% vs 15% in the obesity-specific trials. That's a real difference. It's not a blowout. It's the difference between losing 22 kilos and losing 15 kilos for someone starting at 100. For some people that's the entire decision. For most people it's one input among several.

The four other inputs that matter:

Side effect tolerance. Tirzepatide's GI side effects are slightly more pronounced on average than semaglutide's, especially during dose escalation. Some patients tolerate semaglutide much better. There's no way to predict which group you're in until you try. If you've previously had bad GI reactions to other medications, semaglutide may be the gentler starting point.

What's covered by your insurance. This is the one that actually decides for most patients in the US. Your insurance company has negotiated rebates with one manufacturer or the other through their pharmacy benefit manager. The drug your plan covers preferentially is the drug you should probably take, because the difference in monthly out-of-pocket between covered and uncovered is often the difference between $25 and $1000. The 5-7 percentage point efficacy difference does not justify a 40x cost difference for most patients. Take the covered one and do the lifestyle work; that closes most of the efficacy gap.

Frequency and form. Both are weekly subcutaneous injections at standard dose. Semaglutide also exists as a daily oral pill (Rybelsus at low dose for diabetes; oral Wegovy 25mg approved late 2025 at the higher weight-management dose). If injection is the binding constraint for you, oral semaglutide is the answer. Tirzepatide doesn't have an oral form yet. Foundayo (Lilly's oral GLP-1 from a different molecule entirely, approved April 2026) is in this space but it's not tirzepatide.

Long-term track record. Semaglutide has been in widespread weight-management use since 2021. Tirzepatide since 2023. Both are well-established at this point and the safety data is reassuring on both. If you specifically want the longer track record (some patients do, especially older patients with multiple medications), semaglutide has a couple more years of post-marketing data behind it.

Future-proofing. This one is more speculative. Tirzepatide is getting better follow-on molecules (retatrutide adds glucagon agonism for additional efficacy; phase 3 reads out 2026-2027). Semaglutide has a follow-on too (CagriSema combines semaglutide with cagrilintide for amylin agonism; NDA filed late 2025). Both have meaningful pipeline. If you want to be on the molecule whose successor will be cleanest to switch to, both have viable paths.

How I'd actually decide, given a patient sitting in front of me:

If the patient has commercial insurance, the answer is whichever drug their PBM covers. Run the prior auth, take the savings, do the work. The 5-7 percentage point efficacy gap is real but it's also closeable with adequate protein, resistance training, and patience. A patient on the covered drug who stays on it long-term will outperform a patient on the better drug who quits because they couldn't sustain the cash price.

If the patient is paying cash and budget is tight, semaglutide injectable is often a couple hundred dollars cheaper monthly than tirzepatide injectable in private markets. Worth checking. The oral semaglutide 25mg launched in 2026 at private cash pricing in the $125-175 range globally, which is meaningfully cheaper than either injectable.

If the patient has previously had severe GI reactions to medications, start with semaglutide on the gentler-side-effect-profile bet. Switch to tirzepatide later if needed.

If the patient is healthy, well-insured, has no specific reason to prefer one molecule, and just wants the most effective option, tirzepatide is the answer. The headline 5-7 percentage points is real and 22% weight loss is genuinely better than 15% for someone with significant weight to lose.

If the patient is needle-averse and doesn't have insurance to cover injectables, oral semaglutide 25mg is the answer. Lower efficacy than injectable tirzepatide but real, available, and substantially more accessible.

The conversation goes wrong when "which is better" becomes the only frame. They're both effective. They're both well-tolerated by most patients. The decision is really about which one fits your specific situation, and that requires more inputs than the headline number.